Prolonged reduction of high blood pressure with human nitric oxide synthase gene delivery.

Endothelium-derived nitric oxide (NO) in peripheral vessels has been shown to modulate vascular resistance and blood pressure. We explored the effect of a continuous supply of human endothelial NO synthase (eNOS) on the blood pressure of spontaneously hypertensive rats (SHR) by somatic gene delivery. A DNA construct containing the human eNOS gene fused to the cytomegalovirus promoter/enhancer was injected into SHR through the tail vein. A single injection of the naked eNOS plasmid DNA caused a significant reduction of systemic blood pressure for 5 to 6 weeks in SHR, and the effect continued for up to 10 to 12 weeks after a second injection. The differences were significant from 2 to 12 weeks postinjections (n=6, P<.01). In a separate experiment, L-arginine, the substrate of eNOS, was supplied in drinking water at a concentration of 7.5 g/L for 11 weeks after eNOS gene delivery. A maximal blood pressure reduction of 21 mm Hg in SHR was observed with eNOS DNA compared with that of control SHR injected with vector DNA (181.9+/-1.46 versus 202.7+/-2.79 mm Hg, mean+/-SEM, n=6, P<.01). Human eNOS gene delivery induces significant increases in urinary and aortic cGMP levels and urinary and serum nitrite/nitrate content (P<.05), while no significant differences in body weight, heart rate, water intake, food consumption, or urine excretion were observed. These results indicate that somatic delivery of the human eNOS gene induces a prolonged reduction of high blood pressure and raises the potential of using eNOS gene therapy for hypertension and cardiovascular diseases.

[1]  L. Chao,et al.  Adenovirus-mediated delivery of human kallistatin gene reduces blood pressure of spontaneously hypertensive rats. , 1997, Human gene therapy.

[2]  E. Nava,et al.  Nitric oxide synthase activity in renal cortex and medulla of normotensive and spontaneously hypertensive rats. , 1996, American journal of hypertension.

[3]  L. Chao,et al.  Systemic and portal vein delivery of human kallikrein gene reduces blood pressure in hypertensive rats. , 1996, Human gene therapy.

[4]  T. Imaizumi,et al.  Chronic L-arginine administration attenuates cardiac hypertrophy in spontaneously hypertensive rats. , 1996, Hypertension.

[5]  A. Takeshita,et al.  Chronic inhibition of nitric oxide synthesis causes coronary microvascular remodeling in rats. , 1995, Hypertension.

[6]  L. Chao,et al.  Human atrial natriuretic peptide gene delivery reduces blood pressure in hypertensive rats. , 1995, Hypertension.

[7]  M. Yokoyama,et al.  Nitric oxide synthase isoform activities in kidney of Dahl salt-sensitive rats. , 1995, Hypertension.

[8]  M. Moskowitz,et al.  Hypertension in mice lacking the gene for endothelial nitric oxide synthase , 1995, Nature.

[9]  M. Kohno,et al.  Endothelin Production in Cultured Mesangial Cells of Spontaneously Hypertensive Rats , 1995 .

[10]  L. Chao,et al.  Direct gene delivery of human tissue kallikrein reduces blood pressure in spontaneously hypertensive rats. , 1995, The Journal of clinical investigation.

[11]  L. Chao,et al.  Muscle delivery of human kallikrein gene reduces blood pressure in hypertensive rats. , 1995, Hypertension.

[12]  Y. Kaneda,et al.  Gene therapy inhibiting neointimal vascular lesion: in vivo transfer of endothelial cell nitric oxide synthase gene. , 1995, Proceedings of the National Academy of Sciences of the United States of America.

[13]  J. Liao,et al.  Oxidized Low-density Lipoprotein Decreases the Expression of Endothelial Nitric Oxide Synthase (*) , 1995, The Journal of Biological Chemistry.

[14]  Von der Leyen.  Gene therapy inhibiting neointimal vascular lesion , 1995 .

[15]  A. Hull,et al.  Endothelium-derived relaxing factor and cyclic GMP-dependent vasorelaxation in human chorionic plate arteries. , 1994, Placenta.

[16]  L. Chao,et al.  Human tissue kallikrein induces hypotension in transgenic mice. , 1994, Hypertension.

[17]  K. Pritchard,et al.  Chronic exercise in dogs increases coronary vascular nitric oxide production and endothelial cell nitric oxide synthase gene expression. , 1994, Circulation research.

[18]  S. Snyder,et al.  Nitric oxide: a physiologic messenger molecule. , 1994, Annual review of biochemistry.

[19]  J. Ménard,et al.  Cardiac weight in hypertension induced by nitric oxide synthase blockade. , 1993, Hypertension.

[20]  T. Saruta,et al.  Role of L-arginine-nitric oxide pathway in hypertension , 1993, Journal of hypertension.

[21]  W. Haefeli,et al.  Editorial Comment L‐Arginine in the Clinical Arena: Tool or Remedy? , 1993, Circulation.

[22]  T. Flotte.  Prospects for virus-based gene therapy for cystic fibrosis , 1993, Journal of bioenergetics and biomembranes.

[23]  K. Nishimaki,et al.  Impairment of L-arginine metabolism in spontaneously hypertensive rats. , 1992, Biochemistry international.

[24]  Richard Graham Knowles,et al.  Constitutive and inducible nitric oxide synthases incorporate molecular oxygen into both nitric oxide and citrulline. , 1991, The Journal of biological chemistry.

[25]  J. Leiden,et al.  Systemic delivery of recombinant proteins by genetically modified myoblasts. , 1991, Science.

[26]  H. Blau,et al.  Systemic delivery of human growth hormone by injection of genetically engineered myoblasts. , 1991, Science.

[27]  P. Sanders,et al.  L-arginine abrogates salt-sensitive hypertension in Dahl/Rapp rats. , 1991, The Journal of clinical investigation.

[28]  T. Gettys,et al.  Alterations in mRNA levels, expression, and function of GTP-binding regulatory proteins in adipocytes from obese mice (C57BL/6J-ob/ob). , 1991, The Journal of biological chemistry.

[29]  G. J. Sim,et al.  Dietary arginine fails to protect against cerebrovascular damage in stroke-prone hypertensive rats , 1991, Brain Research.

[30]  R. Rettig,et al.  Development of Genetic Hypertension: Is There a “Critical Phase”? , 1990, Hypertension.

[31]  T. Saruta,et al.  L-arginine-induced hypotension , 1990, The Lancet.

[32]  P. Belloni,et al.  Endothelial cell production of nitrogen oxides in response to interferon gamma in combination with tumor necrosis factor, interleukin-1, or endotoxin. , 1990, Journal of the National Cancer Institute.

[33]  G. Acsadi,et al.  Direct gene transfer into mouse muscle in vivo. , 1990, Science.

[34]  T. Gettys,et al.  Examination of relative rates of cAMP synthesis and degradation in crude membranes of adipocytes treated with hormones. , 1990, Second messengers and phosphoproteins.

[35]  S. Snyder,et al.  Isolation of nitric oxide synthetase, a calmodulin-requiring enzyme. , 1990, Proceedings of the National Academy of Sciences of the United States of America.

[36]  L. Ignarro,et al.  Depletion of arterial L-arginine causes reversible tolerance to endothelium-dependent relaxation. , 1989, Biochemical and biophysical research communications.

[37]  S Moncada,et al.  Role of endothelium-derived nitric oxide in the regulation of blood pressure. , 1989, Proceedings of the National Academy of Sciences of the United States of America.

[38]  O. Griffith,et al.  NG-methylarginine, an inhibitor of endothelium-derived nitric oxide synthesis, is a potent pressor agent in the guinea pig: does nitric oxide regulate blood pressure in vivo? , 1989, Biochemical and biophysical research communications.

[39]  S. Moncada,et al.  Vascular endothelial cells synthesize nitric oxide from L-arginine , 1988, Nature.

[40]  L. Ignarro,et al.  Endothelium-derived relaxing factor produced and released from artery and vein is nitric oxide. , 1987, Proceedings of the National Academy of Sciences of the United States of America.

[41]  G. Brooker,et al.  Radioimmunoassay of cyclic AMP and cyclic GMP. , 1979, Advances in cyclic nucleotide research.

[42]  J. Kuo,et al.  Depressed cardiac cyclic GMP-dependent protein kinase in spontaneously hypertensive rats and its further depression by guanethidine , 1976, Nature.

[43]  G. Brooker,et al.  Femtomole sensitive radioimmunoassay for cyclic AMP and cyclic GMP after 2'0 acetylation by acetic anhydride in aqueous solution. , 1975, Journal of cyclic nucleotide research.

[44]  O. H. Lowry,et al.  Protein measurement with the Folin phenol reagent. , 1951, The Journal of biological chemistry.